In the USA, emergency use authorization sought for fourth Pfizer jab

16 March 2022

Comirnaty developers Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) continue to broaden the impact of the vaccine, with a new regulatory submission in the USA.

The firms have submitted an application to the US Food and Drug Administration for Emergency Use Authorization (EUA) for an additional booster dose for the coronavirus vaccine.

This would cover adults 65 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK